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Abstract
Purpose: Critical Care Nephrology is an emerging sub-specialty of Critical Care.
Despite increasing awareness about the serious impact of acute kidney injury (AKI)
and renal replacement therapy (RRT), important knowledge gaps persist. This report
represents a summary of a 1-day meeting of the AKI section of the European Society
of Intensive Care Medicine (ESICM) identifying priorities for future AKI research.
Methods: International Members of the AKI section of the ESICM were selected and
allocated to one of three subgroups: “AKI diagnosis and evaluation”, “Medical
management of AKI” and “Renal Replacement Therapy for AKI.” Using a modified
Delphi methodology, each group identified knowledge gaps and developed potential
proposals for future collaborative research.
Results: The following key research projects were developed: Systematic reviews: (a)
epidemiology of AKI with stratification by patient cohorts and diagnostic criteria; (b)
role of higher blood pressure targets in patients with hypertension admitted to the
Intensive Care Unit, and (c) specific clearance characteristics of different modalities of
continuous renal replacement therapy (CRRT).
Observational studies: (a) epidemiology of critically ill patients according to AKI
duration, and (b) current clinical practice of CRRT.
Intervention studies:( a) Comparison of different blood pressure targets in critically ill
patients with hypertension, and (b) comparison of clearance of solutes with various
molecular weights between different CRRT modalities.
Conclusion: Consensus was reached on a future research agenda for the AKI section of
the ESICM.
Introduction
Acute kidney injury (AKI) is common during critical illness and associated with serious
short and long-term complications as well as increased use of health care resources
[1–5]. Furthermore, managing AKI is a challenge worldwide and one that requires
multidisciplinary input [6]. In the last decade, tremendous research efforts have been
made and we have vastly improved our understanding of the complexity of AKI but
many important questions regarding AKI remain unresolved [7, 8]. For instance, des-
pite the increasing number of epidemiological studies highlighting the incidence and
outcomes of AKI, this has not translated into any robust strategies to improve patient-
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centred outcomes. Undoubtedly, the heterogenous nature of AKI has contributed to
the challenges of developing effective therapies.
The AKI section of the European Society of Intensive Care Medicine (ESICM)
consists of health care professionals from different countries with a mutual interest in
adult critical care nephrology. One of their key objectives is to support research and to
facilitate clinical and academic collaborations. This approach has already led to success-
ful funding applications, publications in high-impact journals and ongoing research
projects, for instance, AKI-Epi [1], PEACE study (ClinicalTrials.gov Identifier:
NCT02341885), REVERSE-AKI (ClinicalTrials.gov Identifier: NCT03251131), and
PREV-AKI 2 (ClinicalTrials.gov Identifier: NCT03244514).
Clinical practice remains heterogenous and quality standards are lacking. In recognition
of ongoing uncertainties and variation in clinical practice, the ESICM AKI section con-
vened an AKI Round Table (ART) meeting. The objectives of this 1-day meeting were to
determine priorities for future AKI research to be conducted under the umbrella of the
AKI section. This report represents a summary of the conclusions (Table 1).
Methods
ART panel
The Chairs of the AKI section selected current members to join the first ART Meeting.
Nomination was based on expertise and academic track record in the field of AKI and
commitment to the AKI section in general. Twelve members were available and ac-
cepted the invitation. All participants were experts in the field of Critical Care Nephrol-
ogy and research active. A core group of 4 members organized the meeting and agreed
by consensus that the focus of the meeting should be to identify research topics in the
3 key areas of Critical Care Nephrology: “AKI diagnosis and evaluation”, “Medical man-
agement of AKI” and “Renal Replacement Therapy for AKI”. Preceding the meeting,
the participants were allocated to one of the three subgroups. The methodology and
the structure of the meeting were agreed in advance by the core group and discussed
with the participants in order to allow sufficient time for preparation.
ART meeting
The meeting consisted of a one-day workshop which was held in October 2018, 1 day
before the annual ESICM congress. Participants were asked to self-fund their attend-
ance. Importantly, there was no involvement or support from commercial companies.
The structure of the meeting followed a modified Delphi approach. Following an initial
introduction and plenary session outlining the objectives of the meeting, the partici-
pants presented the outcome of their pre-meeting work and subsequently worked in
their allocated groups and developed potential proposals for future research. During
two open panel discussions, each group presented their preliminary and final proposals
to the other two groups for feedback, approval, and consensus. All responses and feed-
back were non-anonymous.
Objectives
The aims of the ART meeting were to identify important areas where evidence and
consensus were lacking and clinical practice was variable and to develop projects for
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future clinical research. Key requirements were that the proposals focussed on clinical
aspects, were relevant to the majority of AKI section members and beyond, allowed
centres from different countries to participate, and that they met global gaps in know-
ledge. The groups were encouraged to refer to the intensive care medicine agenda on
AKI, as published in 2017 [7]. Each subgroup was asked to consider a systematic review
or meta-analysis, an observational cohort study, and a prospective interventional trial, if
possible. It was agreed that proposals needed to be pragmatic, multicentre, collabora-
tive, and feasible without the need for extensive funding. There was full agreement that
all members of the AKI section would be invited to collaborate and that their contribu-
tion would be acknowledged in future publications.
Table 1 Summary of research projects proposed by the ART panel
Epidemiology of AKI Medical therapy of AKI Continuous renal
replacement therapy
Main research
question
What is the epidemiology
of critically ill patients
with AKI of different
durations?
Is a higher target MAP in critically ill
patients with pre-existing hyperten-
sion renoprotective?
What is the difference in
large molecule clearance
between convection versus
diffusion?
Systematic
review of
literature
AKI prevalence Role of higher MAP for patients with
hypertension at risk of development
or progression of AKI
Solute clearance in CVVH vs
CVVHD
Cohort study Retrospective cohort – International survey
RCT –
Target
group
Hypertensive adult patients admitted
to ICU
Patients on CRRT
Intervention
group
Target MAP 80–90 mmHg for at least
48 hours after randomization
treatment with CVVH
Comparator Target MAP 65-75mmHg for at least
48 hours after randomization
Treatment with CVVHD
Primary
outcome
In patients without AKI at
randomization: Primary outcome:
prevention of AKI in 7 days
In patients with AKI and no need for
RRT at randomization: Primary
outcome: MAKE at 28 days
Clearance of beta 2
microglobulin
Sample size
calculation
Hypothesis 1: Expecting 40% of MAKE
30 in patients with AKI in the control
group and a 10% absolute decrease
in the risk (ie. 30% of MAKE 30 in
intervention group)
Target: 182 patients per group (alpha
risk 5%, power 80%)
Target: 240 patients per group (alpha
risk 5%, power 90%)
Hypothesis 2: Expecting 40% of MAKE
30 in patients with AKI in the control
group and a 5% absolute decrease
in the risk (ie 35% of MAKE 30 in
intervention group)
Target: 742 patients per group (alpha
risk 5%, power 80%)
Target: 988 patients per group (alpha
risk 5%, power 90%)
60 patients per group
AKI acute kidney injury, ART acute kidney injury round table, CRRT continuous renal replacement therapy, CVVHD
continuous veno-venous haemodialysis, CVVH continuous veno-venous haemofiltration, MAKE 30 major adverse kidney
events at day 30, MAP mean arterial pressure, RCT randomized controlled trial
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Results
Following detailed review of the existing literature and in-depth discussions, the work-
ing groups identified and developed the following proposals:
A. Group 1: Diagnosis and evaluation of AKI
The reported incidence of AKI is highly variable [6]. This heterogeneity might be ex-
plained by the definitions used (RIFLE, AKIN or KDIGO criteria), differences in patient
populations, case-mix, and clinical setting as well as differences in managing missing
data. Furthermore, the current consensus definition of AKI includes the notion of a
continuum of disease but there is clear evidence of different sub-categories of AKI, for
instance, rapid reversal AKI (duration < 48 h), persistent AKI (duration between 2 and
7 days) and acute kidney disease (up to 90 days). To the best of our knowledge, there
are only limited data evaluating the epidemiology and outcomes of patients with AKI of
different durations (using current criteria, including AKI stages) [9].
i. Proposal for systematic review
Aim: to summarize the existing data related to the epidemiology of AKI with stratifica-
tion by different patient populations and diagnostic criteria in order to increase
granularity
Endpoints: Primary endpoint: overall AKI prevalence; Secondary endpoints: AKI preva-
lence stratified by diagnostic criteria, population type and management of missing data.
Statistical Analysis: meta-regression and multivariable meta-regression
Criteria for study selection: (a) Publication date after 2012; (b) Publication language:
English; (c) Study design: multicentre or > 100 patients recruited from the same center;
and (d) Published as a full paper (no abstract)
Search Strategy: Search in Pubmed and Embase using the following MESH criteria:
“Acute kidney injury” or “AKI”
ii. Proposal for Prevalence Study
Aim: to explore the epidemiology and outcome of critically ill patients according to
AKI duration.
Methods: Observational retrospective multicentre prevalence study including 10 to
20 centres.
Eligibility criteria: Inclusion criteria: all patients admitted to a participating ICU dur-
ing the study period (1 month); Exclusion criteria: end-stage renal disease treated with
chronic dialysis or renal transplant
Definitions: AKI will be defined by the KDIGO criteria (> 26.5 μmol/l or 1.5× baseline
rise in serum creatinine and/or urine output < 0.5 ml/kg/hr for 6 h) [8]; AKI will be
stratified according to the duration of the alteration [persistence of AKI criteria or need
for renal replacement therapy (RRT)].
Endpoints: Primary endpoint: prevalence of AKI according to duration category; Sec-
ondary endpoints: specific mortality for each AKI duration category and renal recovery
at 90 days (absence of AKI criteria and need for RRT)
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B. Group 2: Medical management of AKI
To date, the management of AKI patients focuses on correction of the underlying
cause, avoidance of further renal insults, strategies to prevent progression to a more se-
vere stage of AKI and if possible, facilitation of renal recovery. A key component of this
approach is haemodynamic optimization [8]. However, there is uncertainty about the
exact haemodynamic targets.
The current Kidney Disease Improving Global Outcomes (KDIGO) guideline and
the ESICM recommendations for “Prevention of acute kidney injury and protection
of renal function in the intensive care unit” advise to consider haemodynamic
monitoring early and to aim for a mean arterial pressure (MAP) greater than 65
mmHg to prevent AKI [8, 10]. Concern has been raised that this target may be
too low for individual patient groups. In patients with septic shock, for instance, a
retrospective study concluded that a higher target MAP was associated with better
kidney function [11]. Similarly, a sub-group analysis of a randomized controlled
trial (RCT) comparing different MAP targets suggested that the rate of RRT in pa-
tients with pre-existing hypertension was significantly lower if randomized to the
higher blood pressure group [12]. Among patients with vasopressor-dependent
shock post-cardiac surgery, those with progression of AKI had a greater difference
(deficit) in hemodynamic pressure-related parameters between baseline and within-
ICU stay compared to those without AKI progression [13]. Finally, there are also
data suggesting that a higher MAP in critically ill patients with early AKI is associ-
ated with a reduced risk of progression to more severe AKI [14]. It is our hypoth-
esis that a higher target MAP in critically ill patients with pre-existing
hypertension is associated with better renal outcomes.
i. Proposal for systematic review and meta-analysis
Objective: To explore whether a higher target MAP in patients at risk of AKI
admitted to ICU with known hypertension is associated with improved outcomes
Search criteria: a) RCTs only, including indirect data from RCTs; b) published after
2004; c) published in all languages
Search engines: bibliographic databases (MEDLINE, Embase, Cochrane Library,
CINAHL and Web of Science) from January 2004 to January 2018
Patient population: adult patients (≥18 years) in Critical Care or ICU
Definitions: a) AKI as defined by RIFLE, AKIN or KDIGO criteria; b) Hypertension
as defined by criteria used in the individual studies.
ii. Proposal for randomized controlled trial
Objective: To investigate whether a higher MAP in critically ill patients with
known hypertension is renoprotective.
Patient population: subgroup of critically ill adult patients (i.e. septic shock, post
cardiac surgery or trauma; to be determined at later stage)
Eligibility criteria: Inclusion criteria: (a) admitted to a critical care unit; (b) known
hypertension (i.e. hypertension treated with at least 1 antihypertensive), and c) expected
to stay in ICU for at least 48 h; Exclusion criteria: a) in ICU for > 36 h; b) MAP > 70
mmHg at screening and enrolment without vasopressor support; (c) chronic kidney dis-
ease stage 4 or 5; (d) chronically dialysis dependent ESRD; (e) treatment with RRT at
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time of enrolment; (f) need for ECMO at time of enrolment; (g) any contraindication
to higher or lower MAP target
Group allocation and interventions: Standard care: target MAP 65–75mmHg for at
least 48 h after randomization. Intervention group: target MAP 80–90 mmHg for at
least 48 h after randomization.
Interventions to achieve MAP target: Traditional strategies, including fluids, vaso-
pressors and/or inotropes as per judgement of clinical team. However, starches should
not be used for fluid therapy.
Concomitant treatments: All other aspects of care will be according to local practice
and discretion of the treating clinical team. The decision to initiate RRT will be made
by the clinical team based on traditional clinical parameters.
Outcomes: Depending on whether patients already have AKI or no AKI at time of
randomization:
i. In patients without AKI at randomization:
Primary outcome: prevention of AKI in 7 days; Secondary outcomes: (a) mortality;
(b) creatinine at 28 days; (c) Major adverse kidney event (MAKE) at 28 days; (d)
hospital length of stay; (e) if AKI develops: duration and severity of AKI, including
treatment with RRT; f) adverse events; (g) max dose and duration of catecholamine
treatment
ii. In patients with AKI at enrolment and no immediate need for RRT at
randomization
Primary outcome: MAKE at 28 days; Secondary outcomes: (a) mortality; (b)
creatinine at 28 days; (c) hospital length of stay; (d) duration and severity of AKI;
(e) treatment with RRT; (f) adverse events; (g) max dose and duration of
catecholamine treatment
Potential challenges: The main limitation is the fact that the intervention strategies to
raise MAP and all other concomitant therapies are not standardized. As such, the out-
comes may be influenced by factors other than target MAP, for instance choice and
volume of fluids, use of nephrotoxic drugs and decision to initiate RRT.
C. Group 3: Renal replacement therapy for AKI
The optimal modality of continuous renal replacement therapy (CRRT) for AKI is un-
known and clinical practice is highly variable [15, 16]. To date, precise and exhaustive
information about how CRRT is administered worldwide in 2020 is lacking. There is
no clear evidence that specific modalities of CRRT are superior to others, and detailed
analyses of the effects of CRRT modality on solute clearance are limited [17–20]. It is
assumed that continuous venovenous haemofiltration (CVVH) leads to better clearance
of larger molecules compared to continuous venovenous haemodialysis (CVVHD) due
to solutes being dragged by the solvent. However, this has not been confirmed [21, 22].
In addition, clearance of larger molecules in CVVH may be impacted with time by
clogging related to hemoconcentration inside the filter (depending on the filtration
fraction). Lastly, there are no recent data about the clinical effects of convection versus
diffusion in CRRT.
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i. Proposal for systematic review and meta-analysis
Aim: To systematically search and compile the available data focusing on the com-
parison of CVVH versus CVVHD
Endpoints: Primary endpoint: Solute clearance of various molecules, cytokines and
antibiotics; Secondary endpoints: clinical endpoints
Study Selection: (a) studies comparing CRRT with diffusion (CVVHD) versus
CRRT with convection (CVVH); (b) published as full papers; (c) published in
English
ii. Proposal for observational study
Aim: to capture data related to the current clinical practice of CRRT
Design: International survey sent to institutions worldwide (using ESICM research
network). Methodology: Questions will be primarily focused on CRRT modality to ex-
plore the use of CVVH, CVVHD and CVVHDF. Additional questions will intend to de-
scribe how these 3 modalities are administered in daily clinical practice (dose,
anticoagulation, timing, type of hemofilter, average filter duration, compulsory change
of set every 24 h (yes/no), number of treatment days per year or number of treated pa-
tients/year).
iii. Proposal for interventional study
Hypothesis: Solute clearance is similar between CVVH and CVVHD, including for
middle molecular weight solutes
Aim: To compare clearances of different solutes with various molecular weights be-
tween CVVH and CVVHD over 72 h
Inclusion criteria: Critically ill patients undergoing CRRT
Design: Patients will be randomized in two groups, CVVH or CVVHD. CRRT
dose and anticoagulation (citrate) will be the same in both groups, based on
current KDIGO recommendations [8]. Membranes will be polysulfone-based (e.g.
HF1400, AV1000S) with a standard cut-off of 30,000 Da. Solute clearances will be
calculated at the following time-points: 1 h, 6 h, 12 h, 24 h, 48 h, 72 h. Cross-over
will not be allowed.
Outcomes: Primary outcome: clearance of one large molecular solute (e.g. beta 2
microglobulin); Secondary outcomes: a) time weighted average solute clearances
including urea, creatinine, Interleukin-6, tumor necrosis factor (TNF), kappa Free
Light Chain (25,000 Da), lambda Free Light Chain (50,000 Da), albumin; b) Meta-
bolic endpoints: acid-base status and electrolyte disturbances; c) Hemodynamic im-
pact endpoint: vasopressor treatment; d) filter life; e) survival at 30 day and
hospital discharge; f) CRRT free days; g) Renal recovery: dialysis dependence at
hospital discharge; h) filter survival time
Number of patients per group: 60 patients
Additional remarks: the study will only be conducted in centres where both
modalities (CVVH and CVVHD) can be delivered in order to minimize potential
confounders.
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Discussion
The first ART meeting identified and developed key proposals in the fields of epidemi-
ology, medical management and RRT. In Critical Care Nephrology, there is a clear need
for larger epidemiological research but also small, well defined studies addressing spe-
cific niche aspects, like clearance during CRRT.
The current definition of AKI is very pragmatic but does not account for the hetero-
geneity of AKI as a syndrome [8]. Instead of describing a specific pathophysiological
entity, AKI represents an “umbrella” term for a vast number of conditions characterized
by a rise in serum creatinine or decrease in urine output. In addition, important aspects
related to AKI, including recurrence and clinical context are not incorporated in the
current criteria. Finally, the significance of duration of AKI remains uncertain. This in-
cludes short periods of AKI or rapid reversal of AKI, or AKI lasting for 7 days or lon-
ger, so called “Acute Kidney Disease” (AKD) [8, 23].
The proposals of the working group on diagnosis and definition of AKI will focus on
the epidemiology of AKI in different subgroups of critically ill patients and its etiology
and duration. As such, they will explore the epidemiology and outcomes according to
the current KDIGO definition and investigate the impact of different patterns and du-
rations of AKI [23]. Especially, the two types “rapid reversal of AKI“ (i.e. duration of 48
h or less) and “AKD” (duration up to 90 days) have not been well explored so far. Fi-
nally, the nature of the ESICM AKI network may also allow an investigation of regional
differences in the epidemiology of AKI.
To date, the management of AKI remains supportive with focus on correction of vol-
ume depletion and hypotension, avoidance of further nephrotoxic insults and treatment
of the underlying acute illness. Although this makes sense at first glance, the details for
management at the bedside are scarce or lacking [24]. For instance, there is no consen-
sus on the optimal method of assessing volume status, rate of fluid administration,
haemodynamic targets to prevent or reverse AKI and the optimal strategy to correct
hypotension. Accordingly, the ART panel identified blood pressure as the target of a
pragmatic and feasible future intervention study.
Finally, clinical trials in the field of RRT have established that a higher dose of RRT
does not translate into better outcomes and that regional anticoagulation with citrate is
associated with longer filter life in CRRT. However, other important aspects are still
uncertain, for instance the optimal modality, timing and discontinuation of RRT [16,
24]. Despite several decades of applying convective and diffusive RRT modalities, the
evidence on its use is very limited. At present, the application of diffusive and convect-
ive therapies is mainly driven by pragmatic arguments, and not by evidence. Since
clearance is an essential element of RRT, the RRT working group selected this topic for
further studies: a literature review, an international survey and a randomized controlled
trial. If successful, we believe the results will inform future decision making in Critical
Care Nephrology.
It is fully acknowledged that there are many more areas where clinical practice is
variable and more evidence is urgently required. The suggested proposals by the ART
panel members represent areas of high priority and allow participation and collabor-
ation among all interested ESICM AKI section members and beyond.
In conclusion, the ART panel identified pragmatic and feasible studies that are open
to all ESICM AKI section members to participate. These studies cover the entire
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spectrum of clinical AKI in 3 domains: diagnosis and epidemiology, medical therapy
and RRT. Although achieving consensus among experts is already a major achievement,
we acknowledge that more work is necessary to develop the relevant protocols further,
secure the necessary funding, and recruit collaborators.
The ART meeting was the first of hopefully a series of meetings which aim to develop
and facilitate collaborative research to advance the field of Critical Care Nephrology
and improve the outcome of patients with AKI.
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